Mohamad Mohty

Title: Professor
Position: Full Professor of Hematology, Head of the Hematology and Cellular Therapy Department
Organization: Saint-Antoine Hospital and Sorbonne University in Paris
Country: France

Mohamad Mohty is a French hematologist and researcher currently holds the position of Full Professor of Hematology and Head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He is also the head of a translational research team[2] at the Saint-Antoine Research Centre in Paris.

Dr. Mohty has made significant contributions to the field of hematology and immunobiology, particularly stem cell transplantation, leukemia, and myeloma. In addition to his academic and research roles. He is actively involved in numerous professional societies and organizations, including the European Society for Blood and Marrow Transplantation (EBMT), and the International Academy for Clinical Hematology (IACH).

Dr. Mohty received his medical degree from the University of Montpellier (M.D., 2000), France, and his Ph.D. from the University of Marseille, France (2003). He also undertook post-doctoral work at the Hematology Department of Imperial College, Hammersmith Hospital in London, UK. In 2005, he obtained his Habilitation to Direct Research (Habilitation à diriger les Recherches, HDR), from the Université de la Méditerranée, Marseille, France, which is the highest diploma that can be granted by a French university.

Since 2008, he has been a Professor of clinical hematology and (since 2012) Head of the Clinical Hematology and Cellular Therapy Department at the Saint-Antoine Hospital, Sorbonne University, Paris, France. From 2008 to 2012, he was Professor of Clinical Hematology and head of the stem cell program at the Faculty of Medicine and University Hospital of Nantes, France. From 2002 to 2007, he was Senior Consultant and Associate Professor of Hematology at the Faculty of Medicine of Marseille, and the Regional Cancer Centre Institut Paoli-Calmettes, Département d’Hématologie, Unité de Transplantation et de Thérapie Cellulaire, Marseille, France.
Dr. Mohty started his career in academia with a focus on translational research related to the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs, and hypomethylating agents. His research has also included the development of reduced-toxicity conditioning regimens, immunotherapy, and other aspects of therapy for acute leukemia and multiple myeloma. More recently, he pioneered a cutting-edge research dedicated to the modulation of the microbiota in patients with hematological malignancies.

Dr. Mohty is known for his extensive contributions to the field, including publishing over 900 peer-reviewed articles in leading hematology and immunology journals such as the New Engl. J Med, Blood, J Clin Oncol, The Lancet, The Lancet Oncology, The Lancet Haematology, Nature Reviews, and many other prestigious journals. According to Scopus, he has 33 334 citations by 20,436 documents, worked with 5342 co-authors and has an h-index of 89.

In 2015, Dr Mohty was ranked among the ten most productive authors in hematology worldwide over the last ten years (Kamble et al., Bibliometric Analysis of Hematology during 2004-2013, J. Adv. in Library and Information Sci., 4: 21-25; 2015). He also has been invited to present over five hundred lectures around the world (more than 70 countries visited) related to hematology (especially multiple myeloma), immunology, oncology, and stem cell transplantation/cellular therapy.

Dr Mohty has strong expertise in clinical research and deep knowledge in the field of stem cell transplantation, cellular therapy, and therapy of leukemia and multiple myeloma. Over the last 10 years, he played a key role in the approval of different hematology drugs. He served as the principal investigators for >10 major national protocols in the field of hematology, cellular therapy and stem cell transplantation (equivalent to large NIH grants), and he was the co-investigator of >50 national and international clinical research protocols.

Driven by a strong entrepreneurial spirit, Dr Mohty is regularly consulted by biotechs, clinical stage hematology/oncology companies and industry leaders focusing on treating blood cancers. He has been acting as the key scientific and clinical advisor for different companies (assistance with interactions with EMA, FDA, regulatory bodies, payor organizations, SAB, etc.)

He also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International and as an associate editor for Leukemia, European Journal of Haematology, and Blood Cancer Journal. He is also a regular reviewer for numerous other reputable journals and serves on the editorial board of Blood and Haematologica. Dr. Mohty’s extensive expertise in the field of hematology has made him a highly sought-after speaker and consultant.

Dr Mohty has been actively involved in the scientific community and as a member of societies focused on hematology, immunology, oncology, and stem cell transplantation. He was the Scientific Chair of the 37th annual meeting of EBMT held in Paris April 3-7, 2011. In 2010 and 2017, he was invited by ASH to be part of the educational program. He served as a member of the Steering Committee on Practice Guidelines for ASBMT.

Dr. Mohty has held various leadership positions in professional societies, he is past-president of the European Society for Blood and Marrow Transplantation (EBMT; 2014-2018) and past chairman of the Acute Leukemia Working Party (ALWP; 2010-2014 and 2018-20222) of the EBMT. He is also the founder and current chairman of the International Academy for Clinical Hematology (IACH; 2018) and a board member of the Intergroupe Francophone du Myelome (IFM; since 2005).

He also a member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), Société Française d’Hématologie (SFH), Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), and the European Hematology Association (EHA).